Larkberget

Larkberget ROE

The Return on Equity (ROE) of Larkberget (LARK.ST) as of Oct 21, 2026 is -22.27 %. In the previous year, Return on Equity (ROE) was -62.70 % — a change of -64.48% (higher).

ROE

-22.27 %

YoY

-64.48%

Last updated:

In 2025, Larkberget's return on equity (ROE) was -22.27 %, a -64.48% increase from the -62.70 % ROE in the previous year.

The Larkberget ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-64.27 SEK
Jan 1, 2019
-96.61 SEK
Jan 1, 2020
-43.08 SEK
Jan 1, 2021
13.25 SEK
Jan 1, 2022
-4.05 SEK
Jan 1, 2023
-30.63 SEK
Jan 1, 2024
-62.70 SEK
Jan 1, 2025
-22.27 SEK
The Larkberget ROE history
YEARROEYoY
-22.27 %-64.48%
-62.70 %+104.72%
-30.63 %+656.66%
-4.05 %-130.56%
13.25 %-130.74%
-43.08 %-55.41%
-96.61 %+50.33%
-64.27 %-53.28%
-137.56 %-35.24%
-212.43 %+237.10%
-63.02 %+271.50%
-16.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? CombiGene AB specializes in developing treatments for neurological disorders using gene therapy vectors. The company's platform delivers combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. CombiGene focuses on an epilepsy treatment utilizing an adeno-associated virus (AAV) vector carrying transgenes for NPY and its Y2 receptor. The firm targets neurological and psychiatric diseases in humans and animals through its gene therapy approach. CombiGene AB's products are developed for the treatment of epilepsy and other neurological conditions. The company's platform is designed to deliver multiple therapeutic elements simultaneously via gene therapy vectors. The firm's focus on AAV vectors carrying specific transgenes reflects its strategy to address complex neurological disorders with targeted gene-based therapies. The company's target segments include patients with neurological and psychiatric diseases requiring innovative treatment options. CombiGene AB's development pipeline centers on epilepsy treatment using NPY and Y2 receptor transgenes. The firm's approach involves creating therapies that combine multiple biological components to address disease mechanisms more effectively. Larkberget is one of the most popular companies on Eulerpool.

ROE Details

Decoding Larkberget's Return on Equity (ROE)

Larkberget's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Larkberget's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Larkberget's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Larkberget’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Larkberget stock

Return on Equity (ROE) of Larkberget is -22.27 % in 2025.

Return on Equity (ROE) of Larkberget changed from -62.70 % to -22.27 %, representing a -64.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Larkberget since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Larkberget with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Larkberget

All Key Metrics — Larkberget